Background/Objectives: Chordoma, a rare slow-growing malignant bone tumor, remains therapeutically challenging due to its invasive nature. We examined institutional outcomes comparing imatinib and brachyury-directed vaccines.Methods: We used data from three sites of our quaternary care academic institution to analyze demographics, time to progression, overall survival, and adverse events in chordoma patients treated with imatinib or enrolled in a brachyury vaccine trial.Results: We included a total of 52 patients (8 in the brachyury vaccine cohort and 44 in the imatinib cohort) in the analysis. As expected, sacrococcygeal location was the most predominant in both cohorts: 62.5% in the brachyury cohort and 45.5% in the imatinib cohort. No demographic differences were present between the cohorts. ECOG was similar in both groups (p= 0.796). The primary outcome, time to progression (TTP), was shorter in the brachyury compared to the imatinib cohort (5.6 vs. 13 months,p= 0.0589), almost reaching statistical significance. Overall survival (OS) was comparable, 211 vs. 212 months for the brachyury and imatinib cohorts, respectively (p= 0.277). Although the brachyury vaccine cohort presented a higher incidence of adverse events than the imatinib cohort (75% vs. 31.8%,p= 0.021), the severity was milder.Conclusions: Imatinib showed longer disease control than the brachyury vaccine, though overall survival was similar. Future studies and deeper molecular insights are essential to develop better therapies and improve patient quality of life.
背景/目的：脊索瘤是一种罕见的生长缓慢的恶性骨肿瘤，因其侵袭性而治疗困难。本研究比较了伊马替尼与brachyury靶向疫苗的机构治疗结果。方法：我们利用三级学术医疗机构的三个中心数据，分析了接受伊马替尼治疗或参与brachyury疫苗试验的脊索瘤患者的人口统计学特征、疾病进展时间、总生存期及不良事件。结果：共纳入52例患者（brachyury疫苗组8例，伊马替尼组44例）。两组均以骶尾部肿瘤为主：brachyury组占62.5%，伊马替尼组占45.5%。两组人口学特征无差异，ECOG评分相似（p=0.796）。主要终点指标疾病进展时间在brachyury组更短（5.6个月 vs 13个月，p=0.0589），接近统计学显著性。两组总生存期相当（brachyury组211个月 vs 伊马替尼组212个月，p=0.277）。虽然brachyury组不良事件发生率更高（75% vs 31.8%，p=0.021），但严重程度较轻。结论：伊马替尼较brachyury疫苗展现出更长的疾病控制时间，但两组总生存期相似。未来需通过深入研究分子机制来开发更佳疗法，改善患者生活质量。
肿瘤(癌症)患者之家